NCT02763254

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Cell Medica Ltd · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.

Conditions

• Hodgkin Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Post-transplant Lymphoproliferative Disorder

Interventions

Type	Name	Description
BIOLOGICAL	baltaleucel-T	Autologous EBV-specific T cells

Timeline

• Start date: 2016-11-01
• Primary completion: 2018-02-17
• Completion: 2018-02-17
• First posted: 2016-05-05
• Last updated: 2019-03-26
• Results posted: 2019-03-12

Locations

1 site across 1 country: United States